Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pharmacogenetic aspects of candesartan application for the treatment of arterial hypertension in patients with chronic pyelonephritis].

Likars'ka sprava - 1 Jan 2000

Mormol' I A

Abstract excerpt

Now necessity of the strict control arterial pressure (AP) is conventional at chronic diseases of kidneys. Inhibitors of receptors AT1R (BAR) are recognized all over the world as preparations of the first of some for treatment of renoparenchimal hypertensia. The purpose research--to study of clinical effect of Candesartan at patients with renoparenchimal hypertensia depending on a genotype. Survey 50 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biphenyl Compounds

Share to Blood Pressure

Share to Chronic Disease

Share to Pyelonephritis

Share to Receptor, Angiotensin, Type 1

Share to Tetrazoles

Source

Identifiers

PMID: 25286611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pharmacogenetic aspects of candesartan application for the treatment of arterial hypertension in patients with chronic pyelonephritis].PMID 25286611Read ↗

[Clinical efficiency of candesartan in patients with renoparenchymal hypertension in dependence on genotype of angeotensin II receptors of I type].Semantic proximity Read ↗

[Polymorphism of the angiotensin converting enzyme gene (ACE) and kidney diseases].Semantic proximity Read ↗

[Genetic aspects of development of microalbuminuria in patients with hypertensive disease].Semantic proximity Read ↗

[Individual renal hemodynamic response to chronic angiotensin II receptor blockade and the influence on the renin-angiotensin system gene polymorphisms].Semantic proximity Read ↗

Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms.Semantic proximity Read ↗

[Polymorphism of the angiotensin II type 1 receptor in patients with essential hypertension in Ukrainian population].Semantic proximity Read ↗

[Pharmacogenetics of angiotensin system in non diabetic nephropathy].Semantic proximity Read ↗

Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.Semantic proximity Read ↗

[Renin-angiotensin and kinin-bradykinin genes polymorphism effects on permanent arterial hypertension in children].Semantic proximity Read ↗

[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension].Semantic proximity Read ↗

[Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension].Semantic proximity Read ↗

Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen: results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.